Pharmacologic Considerations for Preexposure Prophylaxis in Transgender Women

Studies of tenofovir disoproxil fumarate (TDF)-emtricitabine (FTC)–based preexposure prophylaxis (PrEP) have not focused on transgendered women who are at disproportionate risk of HIV acquisition. Concerns exist for drug interactions between cross-sex therapy (estradiol, progestins, and spironolacto...

Descripción completa

Detalles Bibliográficos
Autores principales: Anderson, Peter L., Reirden, Daniel, Castillo-Mancilla, Jose
Formato: Online Artículo Texto
Lenguaje:English
Publicado: JAIDS Journal of Acquired Immune Deficiency Syndromes 2016
Materias:
Supplement Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4955879/
https://www.ncbi.nlm.nih.gov/pubmed/27429188
http://dx.doi.org/10.1097/QAI.0000000000001105

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4955879/
https://www.ncbi.nlm.nih.gov/pubmed/27429188
http://dx.doi.org/10.1097/QAI.0000000000001105

Ejemplares similares